Corona Virus Infection, COVID, Myocarditis, Myositis, Sars-CoV2
Conditions
Brief summary
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.
Detailed description
The prospective registry shall provide new insights into muscular involvement associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For that reason consecutive patients with proven corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital, are enrolled. Multimodal assessment of neuromuscular pathology is based on medical history, laboratory biomarkers including inflammation parameters and autoimmune antibodies, vital parameters monitoring, muscle ultrasound, transthoracic echocardiography, electroneurography, as well as electromyography. Inclusion of follow-up visits permit longitudinal and prognostic evaluation of diagnostic and therapeutic interventions (e.g. immunomodulation with immunoglobulins, corticosteroids, or interleukin 6 receptor antagonists).
Interventions
DIAGNOSTIC_TESTlaboratory biomarkers
creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
DIAGNOSTIC_TESTmuscle ultrasound
Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
Sponsors
University Hospital Tuebingen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Exclusion criteria
* active or known history of myopathy or advanced stage neuropathy * refusal to participate in clinical research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of elevated creatine kinase in hyperacute phase | 1 week | Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of two-peak elevation of creatine kinase during acute phase | 30 days | Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19) |
| Rate of myositis-specific antibodies | 24 months | Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up |
| Rate of antimyocardial antibodies | 24 months | Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up |
| Area under the curve (AUC) of elevated creatine kinase | 24 months | Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC) |
| Rate of elevated creatine kinase | 24 months | Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) |
| Peak-levels of troponin | 30 days | Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19) |
| Peak-levels of urine myoglobin | 30 days | Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19) |
| Rate of muscle hyperechogenicity | 24 months | Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) |
| Peak-muscle hyperechogenicity | 24 months | Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) |
| Peak-levels of elevated creatine kinase | 24 months | Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) |
Countries
Germany
Contacts
Primary ContactAlexander Grimm, MD
Backup ContactSven Poli, MD
Outcome results
None listed